Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven

NEXT STORY
The global contrast media/ contrast agents market is projected to reach USD 5.9 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 3.7%
PREV STORY
Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven

NEXT STORY
The global contrast media/ contrast agents market is projected to reach USD 5.9 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 3.7%
PREV STORY
Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

YMCA of Northern Alberta launches Month of Giving– and needs your help in raising $100,000 for your community

author_avatar
NASDAQ Market News

Philips, BioIntelliSense and University of Colorado receive U.S. Department of Defense funding for early COVID-19 detection

author_avatar
NASDAQ Market News

PhaseBio Announces Initiation of Phase 2a Multiple Ascending Dose Study of Once-Weekly Basal Insulin PE0139 in Type 2 Diabetes

MALVERN, Pa., Nov. 9, 2015 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical ...

author_avatar
NASDAQ Market News